Intuitive Surgical, Inc.
http://www.intuitivesurgical.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Intuitive Surgical, Inc.
News We’re Watching: Intuitive Plans da Vinci 5 Launch; Roche’s CGM Plan; ReWalk Rebrands, And More
Medtech Insight's News We're Watching highlights medtech industry developments we are following: Intuitive announced an FDA filing for its da Vinci 5 surgical robot; Roche hits at CGM plans; Abbott launches a new smaller rechargeable deep brain stimulator; CroiValve starts transcatheter tricuspid valve trial; ReWalk rebrands as Lifeward; and more news you may have missed.
News We’re Watching: Activist Investor Causes Kerfuffle At Nevro, Lifespin Launches Antibiotic Dx, And More
Medtech Insight's News We're Watching highlights medtech industry news developments that you may have missed over the last few weeks. Last week, EndoQuest closed a $42m round to support its endoluminal surgery system, Intuitive Ventures closed a $150m round, Noah Surgical announced the first biopsy procedures with its Galaxy technology in Asia, the FDA cleared Smileyscope's VR system to reduce needle anxiety, and Guardant will collaborate with Cancer Research UK.
No, I Am Spartacus – Embecta Joins The Quell Against GLP-1 Hype
Embecta, which recently completed its spin-off from Becton Dickinson, is forging ahead with its insulin injector-based business strategy, GLP-1s be damned.
After Two-Year Delay, J&J Plans To Start Trial Ottava Surgical Robot In 2024
J&J originally projected its Ottava soft-tissue robotic surgery system would enter first-in-human trials in 2022 and reach the market by 2023, but the development has been delayed by technical challenges and COVID-19-related disruptions. Now the company plans to start trials of a four-armed version of the device in about a year.
Company Information
- Industry
-
Medical Devices
-
Surgical Equipment & Devices
- Minimally or Less Invasive
-
Surgical Equipment & Devices
- Other Names / Subsidiaries
-
- Orpheus Medical
- Schölly Fiberoptic GmbH
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice